TG Therapeutics, Inc. (0VGI.L)
USD 32.28
(-6.35%)
USD 32.28
(-6.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 110.79 Million USD | 33.39% |
| 2022 | 83.06 Million USD | 5.08% |
| 2021 | 79.04 Million USD | 88.31% |
| 2020 | 41.97 Million USD | 2.87% |
| 2019 | 40.8 Million USD | 60801.49% |
| 2018 | 67 Thousand USD | -47.5% |
| 2017 | 127.61 Thousand USD | 85.28% |
| 2016 | 68.87 Thousand USD | -67.44% |
| 2015 | 211.54 Thousand USD | -23.13% |
| 2014 | 275.19 Thousand USD | -62.93% |
| 2013 | 742.3 Thousand USD | -76.49% |
| 2012 | 3.15 Million USD | -35.37% |
| 2011 | 4.88 Million USD | -74.03% |
| 2010 | 18.81 Million USD | 868.02% |
| 2009 | 1.94 Million USD | 54.31% |
| 2008 | 1.25 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 800 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 112.53 Million USD | 0.78% |
| 2024 Q1 | 111.66 Million USD | 0.79% |
| 2023 Q3 | 11 Million USD | -2.79% |
| 2023 Q2 | 11.31 Million USD | -2.65% |
| 2023 FY | 110.79 Million USD | 33.39% |
| 2023 Q4 | 110.79 Million USD | 907.14% |
| 2023 Q1 | 11.62 Million USD | -86.0% |
| 2022 FY | 83.06 Million USD | 5.08% |
| 2022 Q4 | 83.06 Million USD | 1.0% |
| 2022 Q1 | 79.05 Million USD | 0.02% |
| 2022 Q2 | 80.4 Million USD | 1.7% |
| 2022 Q3 | 82.23 Million USD | 2.28% |
| 2021 Q2 | 34.84 Million USD | -17.06% |
| 2021 Q3 | 27.48 Million USD | -21.11% |
| 2021 Q4 | 79.04 Million USD | 187.58% |
| 2021 FY | 79.04 Million USD | 88.31% |
| 2021 Q1 | 42 Million USD | 0.08% |
| 2020 Q3 | 41.08 Million USD | 0.14% |
| 2020 Q4 | 41.97 Million USD | 2.17% |
| 2020 FY | 41.97 Million USD | 2.87% |
| 2020 Q2 | 41.02 Million USD | 0.16% |
| 2020 Q1 | 40.96 Million USD | 0.39% |
| 2019 Q1 | 37.72 Million USD | 56211.94% |
| 2019 Q4 | 40.8 Million USD | 3.34% |
| 2019 Q3 | 39.48 Million USD | 4.3% |
| 2019 Q2 | 37.85 Million USD | 0.34% |
| 2019 FY | 40.8 Million USD | 60801.49% |
| 2018 Q1 | 224 Thousand USD | 75.53% |
| 2018 FY | 67 Thousand USD | -47.5% |
| 2018 Q4 | 67 Thousand USD | -26.37% |
| 2018 Q3 | 91 Thousand USD | -56.67% |
| 2018 Q2 | 210 Thousand USD | -6.25% |
| 2017 Q3 | 182.15 Thousand USD | 19.39% |
| 2017 Q2 | 152.56 Thousand USD | -12.65% |
| 2017 Q1 | 174.65 Thousand USD | 153.59% |
| 2017 Q4 | 127.61 Thousand USD | -29.94% |
| 2017 FY | 127.61 Thousand USD | 85.28% |
| 2016 Q4 | 68.87 Thousand USD | -41.2% |
| 2016 Q3 | 117.12 Thousand USD | 29.33% |
| 2016 Q2 | 90.56 Thousand USD | -40.78% |
| 2016 Q1 | 152.91 Thousand USD | -27.72% |
| 2016 FY | 68.87 Thousand USD | -67.44% |
| 2015 Q4 | 211.54 Thousand USD | 16.45% |
| 2015 FY | 211.54 Thousand USD | -23.13% |
| 2015 Q1 | 272.2 Thousand USD | -1.08% |
| 2015 Q2 | 295.36 Thousand USD | 8.51% |
| 2015 Q3 | 181.66 Thousand USD | -38.49% |
| 2014 Q2 | 159.21 Thousand USD | 37.78% |
| 2014 Q1 | 115.55 Thousand USD | -84.43% |
| 2014 Q4 | 275.19 Thousand USD | 50.26% |
| 2014 FY | 275.19 Thousand USD | -62.93% |
| 2014 Q3 | 183.14 Thousand USD | 15.03% |
| 2013 Q3 | 2.94 Million USD | -3.15% |
| 2013 FY | 742.3 Thousand USD | -76.49% |
| 2013 Q4 | 742.3 Thousand USD | -74.81% |
| 2013 Q2 | 3.04 Million USD | -1.92% |
| 2013 Q1 | 3.1 Million USD | -1.74% |
| 2012 FY | 3.15 Million USD | -35.37% |
| 2012 Q1 | 5.34 Million USD | 9.38% |
| 2012 Q3 | 5.05 Million USD | -0.29% |
| 2012 Q2 | 5.07 Million USD | -5.05% |
| 2012 Q4 | 3.15 Million USD | -37.59% |
| 2011 Q3 | 17.6 Million USD | 0.58% |
| 2011 Q4 | 4.88 Million USD | -72.26% |
| 2011 Q1 | 18.91 Million USD | 0.55% |
| 2011 Q2 | 17.5 Million USD | -7.46% |
| 2011 FY | 4.88 Million USD | -74.03% |
| 2010 Q1 | 18.43 Million USD | 848.7% |
| 2010 FY | 18.81 Million USD | 868.02% |
| 2010 Q4 | 18.81 Million USD | 0.87% |
| 2010 Q3 | 18.64 Million USD | 0.75% |
| 2010 Q2 | 18.51 Million USD | 0.41% |
| 2009 Q3 | 1.77 Million USD | 4.66% |
| 2009 Q1 | 1.62 Million USD | 28.84% |
| 2009 Q4 | 1.94 Million USD | 9.22% |
| 2009 Q2 | 1.7 Million USD | 4.78% |
| 2009 FY | 1.94 Million USD | 54.31% |
| 2008 Q3 | 70 Thousand USD | 0.0% |
| 2008 FY | 1.25 Million USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | 1.25 Million USD | 1699.06% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | 324.39 Thousand USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q3 | 70 Thousand USD | 0.0% |
| 2003 Q2 | 70 Thousand USD | 0.0% |
| 2003 Q1 | 70 Thousand USD | -91.25% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | - USD | -100.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | 800 Thousand USD | 0.0% |
| 2002 Q4 | 800 Thousand USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -203.249% |
| Dynavax Technologies Corporation | 256.91 Million USD | 56.875% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -166.802% |
| Perrigo Company plc | 4.07 Billion USD | 97.28% |
| Illumina, Inc. | 2.26 Billion USD | 95.102% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.683% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -10979.5% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.84% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.221% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 36.234% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 95.901% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -310.504% |
| Waters Corporation | 2.35 Billion USD | 95.296% |
| Biogen Inc. | 7.33 Billion USD | 98.49% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -190.77% |
| Evolus, Inc. | 126.54 Million USD | 12.447% |
| Adicet Bio, Inc. | 17.7 Million USD | -525.854% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -156.666% |
| bluebird bio, Inc. | 330.32 Million USD | 66.459% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 79.518% |
| FibroGen, Inc. | 170.45 Million USD | 35.0% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 95.949% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -430.52% |
| Homology Medicines, Inc. | 44.05 Million USD | -151.498% |
| Geron Corporation | 85.89 Million USD | -28.983% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 95.38% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 75.106% |
| Myriad Genetics, Inc. | 145 Million USD | 23.59% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -8693.254% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 3.946% |
| Zoetis Inc. | 6.8 Billion USD | 98.371% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2416.924% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 94.889% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 90.229% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 86.295% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -205.027% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 92.378% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -91.448% |
| Verastem, Inc. | 41.55 Million USD | -166.61% |
| Nektar Therapeutics | 230.4 Million USD | 51.912% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 40.552% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -3504.262% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 92.068% |
| OPKO Health, Inc. | 326.56 Million USD | 66.073% |
| Exelixis, Inc. | 189.94 Million USD | 41.67% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 74.137% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -73274.172% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 19.951% |
| Imunon, Inc. | 1.13 Million USD | -9624.891% |
| Blueprint Medicines Corporation | 774.12 Million USD | 85.688% |
| Insmed Incorporated | 1.2 Billion USD | 90.798% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 92.61% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -94.418% |
| Incyte Corporation | 38.28 Million USD | -189.38% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 87.374% |